

Peter J Trainer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7250782/publications.pdf>

Version: 2024-02-01

100
papers

6,486
citations

87723

38
h-index

64668

79
g-index

104
all docs

104
docs citations

104
times ranked

4125
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of Acromegaly with the Growth Hormone Receptor Antagonist Pegvisomant. <i>New England Journal of Medicine</i> , 2000, 342, 1171-1177.	13.9	782
2	The Diagnosis and Differential Diagnosis of Cushing's Syndrome and Pseudo-Cushing's States. <i>Endocrine Reviews</i> , 1998, 19, 647-672.	8.9	614
3	Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. <i>Lancet</i> , The, 2001, 358, 1754-1759.	6.3	585
4	The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. <i>European Journal of Endocrinology</i> , 2011, 165, 383-392.	1.9	322
5	A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. <i>Clinical Endocrinology</i> , 1995, 43, 545-550.	1.2	211
6	Multidisciplinary management of acromegaly: A consensus. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 667-678.	2.6	183
7	Nitric oxide modulates the release of corticotropin-releasing hormone from the rat hypothalamus in vitro. <i>Brain Research</i> , 1993, 605, 187-192.	1.1	181
8	Quality of Life (QOL) in Patients with Acromegaly Is Severely Impaired: Use of a Novel Measure of QOL: Acromegaly Quality of Life Questionnaire. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3337-3341.	1.8	177
9	Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4146-4154.	1.8	176
10	Glucose Homeostasis and Safety in Patients with Acromegaly Converted from Long-Acting Octreotide to Pegvisomant. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5684-5691.	1.8	171
11	Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1699-1708.	1.8	144
12	The diagnosis and differential diagnosis of Cushing's syndrome. <i>Clinical Endocrinology</i> , 1991, 34, 317-330.	1.2	143
13	A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. <i>Clinical Endocrinology</i> , 2009, 71, 549-557.	1.2	126
14	Endoscopic Transsphenoidal Pituitary Surgery: Evidence of an Operative Learning Curve. <i>Neurosurgery</i> , 2010, 67, 1205-1212.	0.6	123
15	Simultaneous measurement of cortisol and cortisone in human saliva using liquid chromatography-tandem mass spectrometry: Application in basal and stimulated conditions. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 3771-3775.	1.2	122
16	Regulation of cortisol bioavailability effects on hormone measurement and action. <i>Nature Reviews Endocrinology</i> , 2012, 8, 717-727.	4.3	116
17	Expanding the Spectrum of Mutations in GH1 and GHRHR: Genetic Screening in a Large Cohort of Patients with Congenital Isolated Growth Hormone Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3191-3199.	1.8	103
18	The Growth Hormone Secretagogue Hexarelin Stimulates the Hypothalamo-Pituitary-Adrenal Axis via Arginine Vasopressin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2489-2495.	1.8	96

#	ARTICLE	IF	CITATIONS
19	Consensus statement on the standardisation of GH assays. <i>European Journal of Endocrinology</i> , 2006, 155, 1-2.	1.9	91
20	Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11 β -hydroxylase inhibitor metyrapone. <i>Annals of Clinical Biochemistry</i> , 2011, 48, 441-446.	0.8	91
21	Optimizing Control of Acromegaly: Integrating a Growth Hormone Receptor Antagonist into the Treatment Algorithm. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4759-4767.	1.8	85
22	ACROSTUDY: the first 5 years. <i>European Journal of Endocrinology</i> , 2009, 161, S19-S24.	1.9	81
23	Corticosteroids and Pregnancy. <i>Seminars in Reproductive Medicine</i> , 2002, 20, 375-380.	0.5	68
24	Acromegaly—Consensus, What Consensus?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3534-3536.	1.8	67
25	Seeking the Optimal Target Range for Insulin-Like Growth Factor I during the Treatment of Adult Growth Hormone Disorders. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5865-5870.	1.8	63
26	Gender, Body Weight, Disease Activity, and Previous Radiotherapy Influence the Response to Pegvisomant. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 190-195.	1.8	63
27	Control of growth hormone and IGF-1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. <i>Clinical Endocrinology</i> , 2013, 79, 689-699.	1.2	61
28	Treatment of acromegaly improves quality of life, measured by AcroQol. <i>Clinical Endocrinology</i> , 2007, 67, 358-362.	1.2	60
29	Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. <i>European Journal of Endocrinology</i> , 2008, 159, 517-523.	1.9	58
30	Acromegaly surgery in Manchester revisited—The impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission. <i>Clinical Endocrinology</i> , 2012, 76, 399-406.	1.2	57
31	Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3785-e3797.	1.8	54
32	Differential stimulation of cortisol and dehydroandrosterone levels by food in obese and normal subjects: relation to body fat distribution. <i>Clinical Endocrinology</i> , 1996, 45, 699-706.	1.2	53
33	Measurement of salivary cortisol with liquid chromatography-tandem mass spectrometry in patients undergoing dynamic endocrine testing. <i>Clinical Endocrinology</i> , 2010, 72, 17-21.	1.2	53
34	High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry. <i>European Journal of Endocrinology</i> , 2019, 181, 461-472.	1.9	53
35	The effect of an opiate antagonist on the hormonal changes induced by hexarelin. <i>Clinical Endocrinology</i> , 1995, 43, 365-371.	1.2	52
36	Early diagnosis of acromegaly: computers vs clinicians. <i>Clinical Endocrinology</i> , 2011, 75, 226-231.	1.2	47

#	ARTICLE	IF	CITATIONS
37	GH Strongly Affects Serum Concentrations of Mannan-Binding Lectin: Evidence for a New IGF-I Independent Immunomodulatory Effect of GH. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 5383-5388.	1.8	46
38	Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN. <i>European Journal of Endocrinology</i> , 2017, 176, 613-624.	1.9	42
39	Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the <scp>ERCUSYN</scp>. <i>Clinical Endocrinology</i> , 2018, 88, 787-798.	1.2	40
40	Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. <i>Endocrine Connections</i> , 2018, 7, R126-R134.	0.8	39
41	Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. <i>European Journal of Endocrinology</i> , 2018, 178, 399-409.	1.9	37
42	Pituitary-independent effect of octreotide on IGF1 generation. <i>European Journal of Endocrinology</i> , 2009, 160, 543-548.	1.9	36
43	Current status and future opportunities for controlling acromegaly. <i>Pituitary</i> , 2002, 5, 185-196.	1.6	35
44	The Growth Hormone Secretagogue Hexarelin Stimulates the Hypothalamo-Pituitary-Adrenal Axis via Arginine Vasopressin. , 0, .		35
45	Cushing's Syndrome: Therapy Directed at the Adrenal Glands. <i>Endocrinology and Metabolism Clinics of North America</i> , 1994, 23, 571-584.	1.2	34
46	Case for the Wider Adoption of Mass Spectrometry-Based Adrenal Steroid Testing, and Beyond. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4434-4437.	1.8	34
47	The use of mass spectrometry to improve the diagnosis and the management of the HPA axis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2013, 14, 143-157.	2.6	30
48	The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly. <i>European Journal of Endocrinology</i> , 2006, 154, 267-274.	1.9	27
49	Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease. <i>European Journal of Endocrinology</i> , 2010, 162, 677-684.	1.9	27
50	A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4189-4194.	1.8	27
51	A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. <i>European Journal of Endocrinology</i> , 2018, 179, 97-108.	1.9	27
52	l-Arginine is unlikely to exert neuroendocrine effects in humans via the generation of nitric oxide. <i>European Journal of Endocrinology</i> , 1996, 135, 543-547.	1.9	26
53	Exon Splice Enhancer Mutation (GH-E32A) Causes Autosomal Dominant Growth Hormone Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4427-4435.	1.8	26
54	Small Vessel Remodeling and Impaired Endothelial-Dependent Dilatation in Subcutaneous Resistance Arteries from Patients with Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1111-1117.	1.8	26

#	ARTICLE	IF	CITATIONS
55	New causes of hypophysitis. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 101276.	2.2	24
56	Hexarelin as a test of pituitary reserve in patients with pituitary disease. Clinical Endocrinology, 1999, 51, 369-375.	1.2	21
57	Adjuvant immunotherapy: the sting in the tail. European Journal of Cancer, 2020, 132, 207-210.	1.3	20
58	The harmonisation of growth hormone measurements: Taking the next steps. Clinica Chimica Acta, 2014, 432, 68-71.	0.5	19
59	The cardiovascular phenotype of a mouse model of acromegaly. Growth Hormone and IGF Research, 2009, 19, 413-419.	0.5	18
60	Lessons Learned from 15 Years of KIMS and 5 Years of ACROSTUDY. Hormone Research in Paediatrics, 2011, 76, 33-38.	0.8	18
61	IGF-I measurements in the monitoring of GH therapy. Pituitary, 2007, 10, 159-163.	1.6	16
62	Harmonizing Growth Hormone Measurements: Learning Lessons for the Future. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2874-2875.	1.8	14
63	The place of pegvisomant in the management of acromegaly. Expert Opinion on Investigational Drugs, 2001, 10, 1725-1735.	1.9	13
64	Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly. Expert Opinion on Biological Therapy, 2004, 4, 421-425.	1.4	13
65	In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism. European Journal of Endocrinology, 2017, 177, 257-266.	1.9	12
66	Mapping AcroQoL scores to EQ-5D to obtain utility values for patients with acromegaly. Journal of Medical Economics, 2018, 21, 382-389.	1.0	12
67	Growth hormone receptor antagonists therapy for acromegaly. Best Practice and Research in Clinical Endocrinology and Metabolism, 1999, 13, 419-430.	2.2	11
68	Medical treatment in acromegaly. Current Opinion in Pharmacology, 2003, 3, 672-677.	1.7	10
69	The Pituitary Gland and Age-Dependent Regulation of Body Composition. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3664-3674.	1.8	9
70	Transsphenoidal resection in Cushing's disease: definition of success. Clinical Endocrinology, 1993, 39, 701-703.	1.2	8
71	Clinical Use of Pegvisomant for the Treatment of Acromegaly. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2003, 2, 369-374.	1.8	8
72	Pitfalls in the Diagnosis of Acromegaly. Hormone Research in Paediatrics, 2004, 62, 74-78.	0.8	8

#	ARTICLE	IF	CITATIONS
73	Mass spectrometry for the endocrine clinic – much to digest. <i>Clinical Endocrinology</i> , 2013, 78, 344-346.	1.2	7
74	New options for the medical treatment of Cushing's syndrome. <i>Indian Journal of Endocrinology and Metabolism</i> , 2013, 17, 245.	0.2	7
75	Next Generation Medical Therapy for Cushing's Syndrome – Can We Measure a Benefit?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1157-1160.	1.8	7
76	Cushing's syndrome difficulties in diagnosis. <i>Trends in Endocrinology and Metabolism</i> , 1990, 1, 292-295.	3.1	6
77	Evaluation of pituitary function. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2014, 124, 141-149.	1.0	6
78	State-of-the-Art Strategies for the Diagnosis and Management of Acromegaly. , 2001, 11, 223-232.		5
79	Recent developments in the therapy of acromegaly. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 251-256.	1.9	5
80	ACROSTUDY: An Overview. <i>Hormone Research in Paediatrics</i> , 2007, 68, 68-69.	0.8	5
81	Value of Early Post-Operative Growth Hormone Testing in Predicting Long-Term Remission and Residual Disease after Transsphenoidal Surgery for Acromegaly. <i>Neuroendocrinology</i> , 2022, 112, 345-357.	1.2	5
82	A giant's step forward. <i>Clinical Endocrinology</i> , 2002, 56, 423-425.	1.2	4
83	The Challenges of Reliance on Insulin-Like Growth Factor I in Monitoring Disease Activity in Patients with Acromegaly. <i>Hormone Research in Paediatrics</i> , 2004, 62, 83-88.	0.8	4
84	Intractable hypoglycaemia in a patient with advanced carcinoid syndrome successfully treated with hepatic embolization. <i>Hormones</i> , 2016, 15, 118-121.	0.9	4
85	Recalibration of thinking about adrenocortical function assessment: how the "random" cortisol relates to the short synacthen test results. <i>Cardiovascular Endocrinology and Metabolism</i> , 2021, 10, 137-145.	0.5	4
86	High levels of 150-kDa insulin-like growth factor binding protein three ternary complex in patients with acromegaly and the effect of pegvisomant-induced serum IGF-I normalization. <i>Growth Hormone and IGF Research</i> , 2004, 14, 59-65.	0.5	3
87	The place of pegvisomant in the acromegaly treatment algorithm. <i>Growth Hormone and IGF Research</i> , 2004, 14, 101-106.	0.5	3
88	Determinants of the growth hormone nadir during oral glucose tolerance test in adults. <i>European Journal of Endocrinology</i> , 2019, 181, C17-C20.	1.9	3
89	Somatostatin analogue versus growth hormone antagonist treatment for acromegaly: who should get what?. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2003, 10, 265-271.	0.6	2
90	Spuriously Elevated Serum IGF-1 in Adult Individuals with Delayed Puberty: A Diagnostic Pitfall. <i>International Journal of Endocrinology</i> , 2010, 2010, 1-4.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Response to "Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11 β -hydroxylase inhibitor metyrapone"™ by Halsall et al.. Annals of Clinical Biochemistry, 2012, 49, 204-205.	0.8	2
92	What is the value of the 60-minute cortisol measurement in the short synacthen test (SST)? Evidence for the defence. International Journal of Clinical Practice, 2021, 75, e14417.	0.8	2
93	Too much of a good thing. Clinical Endocrinology, 1998, 49, 285-286.	1.2	0
94	Metabolic effects of GH antagonism in patients with acromegaly. Growth Hormone and IGF Research, 2003, 13, S152-S156.	0.5	0
95	Giant leaps forward. Clinical Medicine, 2009, 9, 363-364.	0.8	0
96	Pituitary hormone replacement. Medicine, 2009, 37, 399-402.	0.2	0
97	Pituitary hormone replacement. Medicine, 2013, 41, 504-507.	0.2	0
98	Qualitätssicherung der Analytik von Wachstumshormon und Insulin-Like Growth Factor I bei Erkrankungen der somatotropen Achse. Laboratoriums Medizin, 2015, 39, .	0.1	0
99	Quality assurance in the analysis of growth hormone and insulin-like growth factor I in disorders of the somatotropic axis. Laboratoriums Medizin, 2016, 39, .	0.1	0
100	GHR Antagonist: Efficacy and Safety. , 2011, , 339-357.		0